MoonLake Immunotherapeutics (MLTX) Competitors $9.28 +0.62 (+7.16%) Closing price 04:00 PM EasternExtended Trading$9.24 -0.04 (-0.48%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLTX vs. SMMT, RDY, ASND, VTRS, ROIV, QGEN, ELAN, BBIO, MRNA, and VRNAShould you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Roivant Sciences (ROIV), Qiagen (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Moderna (MRNA), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. MoonLake Immunotherapeutics vs. Its Competitors Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Roivant Sciences Qiagen Elanco Animal Health BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share MoonLake Immunotherapeutics (NASDAQ:MLTX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership. Which has more volatility and risk, MLTX or SMMT? MoonLake Immunotherapeutics has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.13, suggesting that its stock price is 213% less volatile than the S&P 500. Which has preferable earnings and valuation, MLTX or SMMT? MoonLake Immunotherapeutics has higher earnings, but lower revenue than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.78-3.34Summit Therapeutics$700K23,654.47-$221.32M-$1.01-22.07 Does the media favor MLTX or SMMT? In the previous week, MoonLake Immunotherapeutics had 68 more articles in the media than Summit Therapeutics. MarketBeat recorded 79 mentions for MoonLake Immunotherapeutics and 11 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.65 beat MoonLake Immunotherapeutics' score of 0.04 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 7 Very Positive mention(s) 6 Positive mention(s) 32 Neutral mention(s) 7 Negative mention(s) 2 Very Negative mention(s) Neutral Summit Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in MLTX or SMMT? 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is MLTX or SMMT more profitable? MoonLake Immunotherapeutics' return on equity of -40.98% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MoonLake ImmunotherapeuticsN/A -40.98% -35.81% Summit Therapeutics N/A -208.64%-181.28% Do analysts rate MLTX or SMMT? MoonLake Immunotherapeutics presently has a consensus target price of $36.00, suggesting a potential upside of 287.93%. Summit Therapeutics has a consensus target price of $31.29, suggesting a potential upside of 40.36%. Given MoonLake Immunotherapeutics' higher possible upside, research analysts clearly believe MoonLake Immunotherapeutics is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MoonLake Immunotherapeutics 2 Sell rating(s) 9 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.07Summit Therapeutics 5 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.44 SummaryMoonLake Immunotherapeutics beats Summit Therapeutics on 8 of the 15 factors compared between the two stocks. Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLTX vs. The Competition Export to ExcelMetricMoonLake ImmunotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$556.24M$3.35B$6.12B$10.65BDividend YieldN/A2.29%5.69%4.73%P/E Ratio-3.347.8864.1522.85Price / SalesN/A466.25612.81135.18Price / CashN/A47.6737.7861.77Price / Book1.3110.0613.256.70Net Income-$118.94M-$52.22M$3.30B$276.44M7 Day Performance29.43%5.84%4.70%3.13%1 Month Performance-84.39%12.05%8.43%10.21%1 Year Performance-82.06%26.13%88.01%40.35% MoonLake Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLTXMoonLake Immunotherapeutics2.957 of 5 stars$9.28+7.2%$36.00+287.9%-84.3%$556.24MN/A-3.342Trending NewsAnalyst ForecastAnalyst RevisionSMMTSummit Therapeutics3.3 of 5 stars$21.16+1.0%$31.29+47.9%+16.0%$15.56BN/A-20.95110RDYDr. Reddy's Laboratories3.2943 of 5 stars$13.96-1.9%$16.95+21.5%-9.8%$11.87B$334.26B21.1427,811Positive NewsASNDAscendis Pharma A/S3.0432 of 5 stars$191.60-0.2%$244.36+27.5%+47.8%$11.83B$393.54M-37.131,017Positive NewsVTRSViatris1.7687 of 5 stars$9.62+1.1%$10.40+8.1%-12.6%$11.10B$14.74B-3.3232,000ROIVRoivant Sciences3.4967 of 5 stars$15.10-0.5%$19.94+32.0%+42.9%$10.36B$23.23M-21.57860QGENQiagen4.4532 of 5 stars$43.880.0%$49.69+13.2%+10.9%$9.76B$1.98B25.935,765ELANElanco Animal Health2.6896 of 5 stars$19.63+0.1%$18.33-6.6%+41.1%$9.74B$4.44B22.829,000News CoverageAnalyst UpgradeGap UpBBIOBridgeBio Pharma4.2779 of 5 stars$51.96+3.8%$63.94+23.1%+116.4%$9.57B$221.90M-12.70400MRNAModerna4.3113 of 5 stars$25.33+3.4%$41.81+65.1%-54.3%$9.53B$3.24B-3.365,800VRNAVerona Pharma PLC American Depositary Share1.87 of 5 stars$106.61-0.1%$109.00+2.2%+234.0%$9.20B$42.28M-107.6930Positive News Related Companies and Tools Related Companies SMMT Competitors RDY Competitors ASND Competitors VTRS Competitors ROIV Competitors QGEN Competitors ELAN Competitors BBIO Competitors MRNA Competitors VRNA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLTX) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
